RxDoctor Payments Data

Ray Vaughters, MD

Endocrinology, Diabetes & Metabolism · Aiken, SCNPI 1457327587

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $279,381 of the $321,058 with a category attached, or 87.0%. 55 manufacturers reported payments, led by Lilly USA, LLC at 34.0% of the total. Reporting peaked in 2019 at $108,157 and has fallen 98.1% since, to $2,025 in 2025. Among endocrinology, diabetes & metabolism clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$321,058in general payments, 2019–2025

Across 1,134 payments — averaging $283.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$109K
  • Novo Nordisk$96K
  • AstraZeneca$71K
  • Mannkind Corporation$34K
  • Sanofi-aventis U.S. LLC$1K
  • Amgen$1K
  • plus $7K from 49 others

What the payments were for

  • Consulting fees$3,2501%
  • Speaking & faculty fees$279,38187%
  • Travel & lodging$18,9896%
  • Food & beverage$18,9096%
  • Education$5290%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$321,058 in reported general payments places this provider in the 95th percentile of 99 endocrinology, diabetes & metabolism providers in South Carolina.

See all endocrinology, diabetes & metabolism providers in South Carolina

Medicare billing

Part B allowed, 2024
$386,603
Medicare patients
787
Services billed
6,844

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide230$262,464
FarxigaDapagliflozin Propanediol133$100,409
JardianceEmpagliflozin90$86,780
MounjaroTirzepatide49$52,168
TrulicityDulaglutide38$44,489
RybelsusSemaglutide25$26,862
JanuviaSitagliptin Phosphate38$26,025
Tresiba Flextouch U-100Insulin Degludec41$19,479
Bydureon BciseExenatide Microspheres16$13,403
Fiasp FlextouchInsulin Aspart (Niacinamide)16$13,298
Novolog FlexpenInsulin Aspart43$9,386
JanumetSitagliptin Phos/Metformin Hcl13$7,479
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog17$5,951
Humalog Kwikpen U-100Insulin Lispro35$5,128
Insulin Lispro Kwikpen U-100Insulin Lispro18$3,991

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$96,195$289,326255 claims
AstraZenecaFarxiga$71,414$100,409133 claims
Lilly USA, LLCMounjaro, Trulicity$109,189$96,65787 claims
Boehringer IngelheimJardiance$255$86,78090 claims
MerckJanuvia, Janumet$198$33,50451 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$27$3,169278 claims
AbbVieSynthroid$49$1,52515 claims
Sanofi-aventis U.S. LLCLantus$1,396$74212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 99 endocrinology, diabetes & metabolism providers in South Carolina.

Other endocrinology, diabetes & metabolism in Aiken

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →